Home Cart Sign in  
Chemical Structure| 32619-42-4 Chemical Structure| 32619-42-4

Structure of Oleuropein
CAS No.: 32619-42-4

Chemical Structure| 32619-42-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Oleuropein is an antioxidant polyphenol isolated from the herb of Olea europaea L..

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Oleuropein

CAS No. :32619-42-4
Formula : C25H32O13
M.W : 540.51
SMILES Code : O=C(C1=CO[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)/C([C@@H]1CC(OCCC3=CC=C(O)C(O)=C3)=O)=C/C)OC
MDL No. :MFCD16879008

Safety of Oleuropein

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
LLC cells 25–250 µM 120 h To evaluate the inhibitory effect of Oleuropein on LLC cell growth PMC10912768
SH-SY5Y cells 50 μM Induced autophagy via Ca2+/CaMKKβ/AMPK/mTOR signaling axis, increasing Beclin-1 levels PMC6943788
HONE-1 cells 200 μM 24 h To evaluate the effect of Oleuropein on radiation sensitivity in HONE-1 cells, results showed that Oleuropein significantly enhanced the radiation sensitivity of the cells. PMC5216549
HNE-1 cells 200 μM 24 h To evaluate the effect of Oleuropein on radiation sensitivity in HNE-1 cells, results showed that Oleuropein significantly enhanced the radiation sensitivity of the cells. PMC5216549
Human endometrial stromal cells (HESCs) 200 µg/ml 3 days Evaluate the selective growth inhibition of endometriotic stromal cells by oleuropein, which significantly suppressed cells with high ERβ expression. PMC9682776
Immortalized human endometrial epithelial cells (IHEECs:ERB) 10 nM 24 h Investigate the effect of oleuropein on ERβ subcellular localization, oleuropein inhibited estradiol-induced nuclear translocation of ERβ. PMC9682776
HeLa cells 10 nM 24 h Screening for ERβ-selective inhibitors, oleuropein significantly inhibited ERβ activity. PMC9682776
MDSCs and TAMs 50 µM 7 days To evaluate the reprogramming capacity of Oleuropein on MDSCs and TAMs PMC10912768
H1299 cells 50–250 µM 120 h To evaluate the inhibitory effect of Oleuropein on H1299 cell growth PMC10912768
A549 cells 50–250 µM 120 h To evaluate the inhibitory effect of Oleuropein on A549 cell growth PMC10912768
HTR-8/SVneo cells 10 µM and 100 µM 24 h Evaluation of oleuropein's protective effects against oxidative stress, showing significant improvement in antioxidant status, prevention of protein and lipid damage, and reduction in iNOS levels. PMC9855078

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
BALB/C nude mice Nasopharyngeal carcinoma xenograft model Oral administration via drinking water 1% in drinking water From day 7 to day 21 To evaluate the effect of Oleuropein on radiation sensitivity in nasopharyngeal carcinoma xenograft model, results showed that Oleuropein significantly enhanced the tumor's sensitivity to radiation. PMC5216549
C57BL/6 mice High-fat diet-induced nonalcoholic steatohepatitis (NASH) model Dietary supplementation 0.05% (w/w) Continued for 6 months To evaluate the anti-fibrotic effects of oleuropein in a HFD-induced NASH model. Results showed that oleuropein significantly reduced HOMA-IR and leptin levels, and decreased the expression of α-SMA and collagen type I, indicating that oleuropein may effectively prevent the progression of steatohepatitis and fibrosis. PMC3972787
C57BL/6J mice Surgically induced endometriosis model Oral 25 mg/kg Once daily for 21 days Assess the inhibitory effect of oleuropein on endometriosis progression, 25 mg/kg oleuropein significantly suppressed ectopic lesion growth and improved pregnancy rates. PMC9682776
C57BL/6 mice LLC and MC38 tumor models Intraperitoneal injection 300 µg Every other day for 8 days To evaluate the antitumor effects of Oleuropein alone or in combination with anti-PD-1 antibodies PMC10912768
Caenorhabditis elegans Wild-type N2 worms NGM medium treatment 440 µM 48-hour pretreatment Oleuropein significantly extended the lifespan of C. elegans by 22.30% and enhanced resistance to heat and oxidative stress. PMC8614835
Neonatal piglets Brain hypoxia-ischemia and hypothermia model Intravenous injection 2.7 mg/kg IV initial dose, followed by 0.7 mg/kg IV every hour Initial dose followed by every 2 hours until the end of the experiment To investigate the activation of brain proteasomes by Oleuropein under conditions of brain hypoxia-ischemia and hypothermia. Results showed that OLE increased the initial neocortical proteasome activity after hypothermia. PMC8391411

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT03093753 Hyperglycemia Not Applicable Completed - -
NCT01479699 Absorption and Metabolism ... More >> Effect on Vascular Function Effect on Cytokine Concentrations Less << Not Applicable Completed - United Kingdom ... More >> Hugh Sinclair Unit of Human Nutrition, University of Reading Reading, Berkshire, United Kingdom, RG6 5SG Less <<
NCT03072108 Knee Discomfort ... More >> Knee Pain Less << Not Applicable Completed - Belgium ... More >> Centre Hospitalier Universitaire de Liège Liege, Belgium, 4000 Less <<
NCT03362996 Mild Cognitive Impairment Phase 2 Recruiting May 15, 2019 Greece ... More >> Greek Association of Alzheimer's Disease and Related Disordeers Recruiting Thessaloniki, Greece, 54248 Contact: Ersi Grammatikou, Msc    00302310351451 ext 68       Contact: Moesis Gialaouzidis, BSc    00302310351451 ext 23    moses_gf@hotmail.com Less <<
NCT02421835 Pre Hypertension Not Applicable Completed - United Kingdom ... More >> Hugh Sinclair Unit of Human Nutrition Reading, Berkshire, United Kingdom, RG6 6AP Less <<
NCT02669693 Diabetes Not Applicable Completed - United Kingdom ... More >> School of Food Science and Nutrition, University of Leeds Leeds, West Yorkshire, United Kingdom, LS2 9JT Less <<
NCT00789425 Osteoporosis ... More >>Osteopenia Less << Phase 2 Completed - Poland ... More >> Osteoporosis Outpatient of the Institute of Agricultural Medicine Lublin, Poland, 20-950 Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.85mL

0.37mL

0.19mL

9.25mL

1.85mL

0.93mL

18.50mL

3.70mL

1.85mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories